These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 27157696)

  • 1. APOL1 renal-risk genotypes associate with longer hemodialysis survival in prevalent nondiabetic African American patients with end-stage renal disease.
    Ma L; Langefeld CD; Comeau ME; Bonomo JA; Rocco MV; Burkart JM; Divers J; Palmer ND; Hicks PJ; Bowden DW; Lea JP; Krisher JO; Clay MJ; Freedman BI
    Kidney Int; 2016 Aug; 90(2):389-395. PubMed ID: 27157696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. APOL1 allelic variants are associated with lower age of dialysis initiation and thereby increased dialysis vintage in African and Hispanic Americans with non-diabetic end-stage kidney disease.
    Tzur S; Rosset S; Skorecki K; Wasser WG
    Nephrol Dial Transplant; 2012 Apr; 27(4):1498-505. PubMed ID: 22357707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coding variants in nephrin (NPHS1) and susceptibility to nephropathy in African Americans.
    Bonomo JA; Ng MC; Palmer ND; Keaton JM; Larsen CP; Hicks PJ; ; Langefeld CD; Freedman BI; Bowden DW
    Clin J Am Soc Nephrol; 2014 Aug; 9(8):1434-40. PubMed ID: 24948143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival Advantage of African American Dialysis Patients with End-Stage Renal Disease Causes Related to APOL1.
    Lertdumrongluk P; Streja E; Rhee CM; Moradi H; Chang Y; Reddy U; Tantisattamo E; Kalantar-Zadeh K; Kopp JB
    Cardiorenal Med; 2019; 9(4):212-221. PubMed ID: 30995638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. End-stage renal disease in African Americans with lupus nephritis is associated with APOL1.
    Freedman BI; Langefeld CD; Andringa KK; Croker JA; Williams AH; Garner NE; Birmingham DJ; Hebert LA; Hicks PJ; Segal MS; Edberg JC; Brown EE; Alarcón GS; Costenbader KH; Comeau ME; Criswell LA; Harley JB; James JA; Kamen DL; Lim SS; Merrill JT; Sivils KL; Niewold TB; Patel NM; Petri M; Ramsey-Goldman R; Reveille JD; Salmon JE; Tsao BP; Gibson KL; Byers JR; Vinnikova AK; Lea JP; Julian BA; Kimberly RP;
    Arthritis Rheumatol; 2014 Feb; 66(2):390-6. PubMed ID: 24504811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hemostatic Factors, APOL1 Risk Variants, and the Risk of ESRD in the Atherosclerosis Risk in Communities Study.
    Tin A; Grams ME; Maruthur NM; Astor BC; Couper D; Mosley TH; Fornage M; Parekh RS; Coresh J; Kao WH
    Clin J Am Soc Nephrol; 2015 May; 10(5):784-90. PubMed ID: 25887069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sickle cell trait is not independently associated with susceptibility to end-stage renal disease in African Americans.
    Hicks PJ; Langefeld CD; Lu L; Bleyer AJ; Divers J; Nachman PH; Derebail VK; Bowden DW; Freedman BI
    Kidney Int; 2011 Dec; 80(12):1339-43. PubMed ID: 21849968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic variation in APOL1 associates with younger age at hemodialysis initiation.
    Kanji Z; Powe CE; Wenger JB; Huang C; Ankers E; Sullivan DA; Collerone G; Powe NR; Tonelli M; Bhan I; Bernhardy AJ; Dibartolo S; Friedman D; Genovese G; Pollak MR; Thadhani R
    J Am Soc Nephrol; 2011 Nov; 22(11):2091-7. PubMed ID: 21997398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. APOL1 associations with nephropathy, atherosclerosis, and all-cause mortality in African Americans with type 2 diabetes.
    Freedman BI; Langefeld CD; Lu L; Palmer ND; Smith SC; Bagwell BM; Hicks PJ; Xu J; Wagenknecht LE; Raffield LM; Register TC; Carr JJ; Bowden DW; Divers J
    Kidney Int; 2015 Jan; 87(1):176-81. PubMed ID: 25054777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic association and gene-gene interaction analyses in African American dialysis patients with nondiabetic nephropathy.
    Bostrom MA; Kao WH; Li M; Abboud HE; Adler SG; Iyengar SK; Kimmel PL; Hanson RL; Nicholas SB; Rasooly RS; Sedor JR; Coresh J; Kohn OF; Leehey DJ; Thornley-Brown D; Bottinger EP; Lipkowitz MS; Meoni LA; Klag MJ; Lu L; Hicks PJ; Langefeld CD; Parekh RS; Bowden DW; Freedman BI;
    Am J Kidney Dis; 2012 Feb; 59(2):210-21. PubMed ID: 22119407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of APOL1 variants with mild kidney disease in the first-degree relatives of African American patients with non-diabetic end-stage renal disease.
    Freedman BI; Langefeld CD; Turner J; Núñez M; High KP; Spainhour M; Hicks PJ; Bowden DW; Reeves-Daniel AM; Murea M; Rocco MV; Divers J
    Kidney Int; 2012 Oct; 82(7):805-11. PubMed ID: 22695330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of Association of the APOL1 G3 Haplotype in African Americans with ESRD.
    Palmer ND; Ng MC; Langefeld CD; Divers J; Lea JP; Okusa MD; Kimberly RP; Bowden DW; Freedman BI
    J Am Soc Nephrol; 2015 May; 26(5):1021-5. PubMed ID: 25249559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population-based risk assessment of APOL1 on renal disease.
    Friedman DJ; Kozlitina J; Genovese G; Jog P; Pollak MR
    J Am Soc Nephrol; 2011 Nov; 22(11):2098-105. PubMed ID: 21997396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effects of MYH9 and APOL1 risk variants on FRMD3 Association with Diabetic ESRD in African Americans.
    Freedman BI; Langefeld CD; Lu L; Divers J; Comeau ME; Kopp JB; Winkler CA; Nelson GW; Johnson RC; Palmer ND; Hicks PJ; Bostrom MA; Cooke JN; McDonough CW; Bowden DW
    PLoS Genet; 2011 Jun; 7(6):e1002150. PubMed ID: 21698141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. APOL1 risk variants, race, and progression of chronic kidney disease.
    Parsa A; Kao WH; Xie D; Astor BC; Li M; Hsu CY; Feldman HI; Parekh RS; Kusek JW; Greene TH; Fink JC; Anderson AH; Choi MJ; Wright JT; Lash JP; Freedman BI; Ojo A; Winkler CA; Raj DS; Kopp JB; He J; Jensvold NG; Tao K; Lipkowitz MS; Appel LJ; ;
    N Engl J Med; 2013 Dec; 369(23):2183-96. PubMed ID: 24206458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apolipoprotein L1 nephropathy risk variants associate with HDL subfraction concentration in African Americans.
    Freedman BI; Langefeld CD; Murea M; Ma L; Otvos JD; Turner J; Antinozzi PA; Divers J; Hicks PJ; Bowden DW; Rocco MV; Parks JS
    Nephrol Dial Transplant; 2011 Nov; 26(11):3805-10. PubMed ID: 21931123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical phenotype of APOL1 nephropathy in young relatives of patients with end-stage renal disease.
    Anyaegbu EI; Shaw AS; Hruska KA; Jain S
    Pediatr Nephrol; 2015 Jun; 30(6):983-9. PubMed ID: 25530085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genome-wide association studies suggest that APOL1-environment interactions more likely trigger kidney disease in African Americans with nondiabetic nephropathy than strong APOL1-second gene interactions.
    Langefeld CD; Comeau ME; Ng MCY; Guan M; Dimitrov L; Mudgal P; Spainhour MH; Julian BA; Edberg JC; Croker JA; Divers J; Hicks PJ; Bowden DW; Chan GC; Ma L; Palmer ND; Kimberly RP; Freedman BI
    Kidney Int; 2018 Sep; 94(3):599-607. PubMed ID: 29885931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Testing for High-Risk APOL1 Alleles in Potential Living Kidney Donors.
    Riella LV; Sheridan AM
    Am J Kidney Dis; 2015 Sep; 66(3):396-401. PubMed ID: 26049628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. APOL1 Genotype, Kidney and Cardiovascular Disease, and Death in Older Adults.
    Mukamal KJ; Tremaglio J; Friedman DJ; Ix JH; Kuller LH; Tracy RP; Pollak MR
    Arterioscler Thromb Vasc Biol; 2016 Feb; 36(2):398-403. PubMed ID: 26634651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.